LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)

• Phase: Phase 4

Details

• Lead Sponsor: UCB Pharma
• Treatments: Cetirizine; Desloratadine; Levocetirizine

Criteria

Inclusion Criteria:

• At least 2-year history of Allergic Rhinitis that became symptomatic during the annual grass pollen season.

• A skin test for grass pollens positive:

• Have rhinitis symptoms of such severity that the mean T4SS over the baseline period must be 6.

Exclusion Criteria:

• Have an associated asthma requiring corticosteroid treatment,

• Have an atopic dermatitis or an urticaria requiring an antihistamine treatment or the administration of oral or topical corticosteroids,